Effect of aspartame-derived phenylalanine on neutral amino acid uptake in human brain: a positron emission tomography study.
Effect of aspartame-derived phenylalanine on neutral amino acid uptake in human brain: a positron emission tomography study.
复制标题
阿斯巴甜衍生的苯丙氨酸对人脑中性氨基酸摄取的影响:正电子发射断层扫描研究。
DOI:
10.1111/j.1471-4159.1991.tb02047.x
复制
发表时间:
1991
影响因子:
4.7
通讯作者:
Agranoff,BW
中科院分区:
文献类型:
--
作者:
Koeppe,RA;Shulkin,BL;Rosenspire,KC;Shaw,LA;Betz,AL;Mangner,T;Price,JC;Agranoff,BW
The possible effects of elevation of the plasma phe‐nylalanine level secondary to the ingestion of aspartame on brain amino acid uptake in human subjects have been investigated by means of positron emission tomography (PET). 1‐[11C]Aminocyclohexanecarboxylate ([11C]ACHC) is a poorly metabolized synthetic amino acid that crosses the blood‐brain barrier by the same carrier that transports naturally occurring large neutral amino acids. Quantitative test‐retest PET studies were performed on 15 individuals. Seven received two identical baseline scans, whereas eight received a baseline scan followed by a scan performed ∼40–45 min following ingestion of an orange‐flavored beverage containing 34 mg/kg of body weight of the low‐calorie sweetener aspartame, a dose equivalent to the amount in 5 L of diet soft drink consumed all at once by the study subjects, weighing an average of 76 kg. The 40–45‐min interval was selected to maximize the detection of possible decreases in ACHC uptake resulting from increased competition for the carrier, because the plasma phenylalanine level is known to peak at this time. We observed an 11.5% decrease in the amino acid transport rate constant Kt and a smaller decrease in the tissue distribution volume of ACHC (6%). Under conditions of normal dietary use, aspartame is thus unlikely to cause changes in brain amino acid uptake that are measurable by PET.